mitochondria-targeted antioxidant ss-31 as a potential novel ophthalmic drug for neuroprotection in glaucoma
نویسندگان
چکیده
glaucoma is the second leading cause of irreversible blindness and a neurodegenerative disease with a complex pathogenesis. increasing evidence suggests that oxidative stress and mitochondrial dysfunction have crucial roles in most neurodegenerative diseases such as glaucoma. the conventional clinical treatment for glaucoma is lowering the intraocular pressure (iop). some patients have normal iop, whereas other patients appear to obtain adequate control of iop after filtration surgery or medication. however, these patients still experience progressive visual field loss. vision loss in glaucoma is attributed to retinal ganglion cell (rgc) apoptosis. much recent research demonstrates that the link between oxidative stress and mitochondrial dysfunction is a major cause of rgcs apoptosis. how oxidative stress can lead to rgcs apoptosis in glaucoma is unclear but may involve the neurotoxic effects of oxidative stress-induced mitochondrial dysfunction and/or damage from reactive oxygen species (ros). investigations are needed concerning the mitochondria as effective targets for potential therapeutic interventions to maintain mitochondrial function and reduce oxidative stress, and thereby delay or stop rgc loss and prolong visual function. the mitochondria-targeted antioxidant szeto-schiller (ss) peptide is a candidate molecule. szeto-schiller-31 (h-d-arg-dmt-lys-phe-nh2) is an attractive mitochondria-targeted–antioxidant that can protect the mitochondria and rgcs against oxidative damage. therefore, we suggest ss-31 as a novel neuroprotective ophthalmic drug for protecting rgcs in glaucoma.
منابع مشابه
Mitochondria-Targeted Antioxidant SS-31 is a Potential Novel Ophthalmic Medication for Neuroprotection in Glaucoma
Glaucoma is the second leading cause of irreversible blindness and a neurodegenerative disease with a complex pathogenesis. Increasing evidence suggests that oxidative stress and mitochondrial dysfunction have crucial roles in most neurodegenerative diseases such as glaucoma. The conventional clinical treatment for glaucoma is lowering the intraocular pressure (IOP). Some patients have normal I...
متن کاملMitochondria-targeted peptide SS-31 attenuates renal injury via an antioxidant effect in diabetic nephropathy.
Oxidative stress is implicated in the pathogenesis of diabetic kidney injury. SS-31 is a mitochondria-targeted tetrapeptide that can scavenge reactive oxygen species (ROS). Here, we investigated the effect and molecular mechanism of mitochondria-targeted antioxidant peptide SS-31 on injuries in diabetic kidneys and mouse mesangial cells (MMCs) exposed to high-glucose (HG) ambience. CD-1 mice un...
متن کاملP14: Mitochondria as a Target for Drug Therapy in Epilepsy
لطفاً به چکیده انگلیسی مراجعه شود.
متن کاملOphthalmic Drug Delivery in Glaucoma—A Review
Glaucoma is a progressive optic neuropathy and medical therapy is the initial option for the treatment of this potentially blinding condition. Topical instillation of eye drops from the bottle is the most common glaucoma drug delivery form. Due to limited permeability of anterior ocular surface, natural clearance and drainage, eye drops contain large amounts of inactive ingredients. Effective p...
متن کاملToxicity of Neurons Treated with Herbicides and Neuroprotection by Mitochondria-Targeted Antioxidant SS31
The purpose of this study was to determine the neurotoxicity of two commonly used herbicides: picloram and triclopyr and the neuroprotective effects of the mitochondria-targeted antioxidant, SS31. Using mouse neuroblastoma (N2a) cells and primary neurons from C57BL/6 mice, we investigated the toxicity of these herbicides, and protective effects of SS1 peptide against picloram and triclopyr toxi...
متن کاملمنابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
medical hypothesis, discovery and innovation ophthalmology journalجلد ۴، شماره ۳، صفحات ۰-۰
میزبانی شده توسط پلتفرم ابری doprax.com
copyright © 2015-2023